The new atypical antipsychotics: a review of pharmacoeconomic studies

Expert Opinion on Pharmacotherapy
D A Revicki

Abstract

The pharmacoeconomic evaluation of atypical antipsychotics for the treatment of schizophrenia involves documentation of clinical effectiveness, quality of life and medical cost outcomes. The findings of pharmacoeconomic studies assist psychiatrists and mental healthcare decision-makers in identifying therapies that provide the greatest benefit to patients at the most acceptable cost. The cost-effectiveness of the newer atypical antipsychotics has been examined using non-controlled cohort studies (either retrospective or prospective), modelling studies or randomised clinical trials. The evidence, from a variety of studies, indicates that clozapine is a cost-effective treatment for neuroleptic refractory schizophrenia. Risperidone and olanzapine may be cost neutral, or at best slightly cost saving, compared with conventional antipsychotics, although they do improve patient clinical effectiveness and quality of life outcomes. There is too little data on pharmacoeconomic outcomes for sertindole and quetiapine to make any conclusions about their cost-effectiveness in treating schizophrenia.

References

Jan 1, 1984·Schizophrenia Bulletin·D W HeinrichsW T Carpenter
Nov 1, 1993·The American Journal of Psychiatry·H Y MeltzerB Snitz
Jan 1, 1993·The British Journal of Psychiatry : the Journal of Mental Science·L M Davies, M F Drummond
Jan 1, 1995·Schizophrenia Bulletin·R W Buchanan
Sep 1, 1997·Psychiatric Services : a Journal of the American Psychiatric Association·G VialeB J Lawrence
Dec 24, 1997·Psychiatric Services : a Journal of the American Psychiatric Association·M A DellvaC M Beasley
Apr 2, 1998·Clinical Therapeutics·A DaviesI Schweitzer
Aug 26, 1998·Psychiatric Services : a Journal of the American Psychiatric Association·D J LuchinsC G Fichtner
Nov 26, 1998·The British Journal of Psychiatry : the Journal of Mental Science·P V TranC M Beasley
Dec 18, 1998·Psychiatric Services : a Journal of the American Psychiatric Association·N BliedenC L Arfken
Dec 8, 1996·PharmacoEconomics·A G AwadR J Heslegrave
Oct 28, 1999·PharmacoEconomics·R H Foster, K L Goa
Apr 20, 2002·The Journal of Mental Health Policy and Economics·M. F. DrummondP. Shadwell
Mar 29, 2008·Clinical Drug Investigation·J A SacristánUNKNOWN Spanish Group for the Study of Olanzapine in Treatment-Refractory Schizophrenia

❮ Previous
Next ❯

Citations

Jun 7, 2005·Expert Opinion on Pharmacotherapy·Hans-Jürgen Möller
Nov 11, 2003·Current Medical Research and Opinion·Ibrahim S Al-ZakwaniTara R Cockerham
Jul 17, 2009·Schizophrenia Research·Emilio SacchettiUNKNOWN MOZART Study Group
Mar 10, 2009·Schizophrenia Research·Emilio SacchettiUNKNOWN INITIATE Study Group
Apr 10, 2003·The Psychiatric Clinics of North America·Robin Emsley, Piet Oosthuizen
Oct 27, 2004·European Psychiatry : the Journal of the Association of European Psychiatrists·Ibrahim ErenVesile Altinyazar

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antipsychotic Drugs

Antipsychotic drugs are a class of medication primarily used to manage psychosis (including delusions, hallucinations, paranoia or disordered thought), principally in schizophrenia and bipolar disorder. Discover the latest research on antipsychotic drugs here

© 2021 Meta ULC. All rights reserved